Pancreatic Cancer

>

Latest News

Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer
Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

March 26th 2025

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic neuroendocrine tumors.
FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors

March 26th 2025

OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC
OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC

March 12th 2025

CAN-2409/Valacyclovir Plus SOC Demonstrates Positive Survival in PDAC
CAN-2409/Valacyclovir Plus SOC Demonstrates Positive Survival in PDAC

February 27th 2025

Post hoc analysis of the phase 3 NAPOLI 3 trial assessed how dose reductions in liposomal irinotecan/oxaliplatin affect OS in NALIRIFOX-treated PDAC.
Lower Liposomal Irinotecan/Oxaliplatin Doses Do Not Worsen PDAC Outcomes

January 25th 2025